Clinical Evaluation of a Line-Probe Assay for Tuberculosis Detection and Drug-Resistance Prediction in Namibia

Günther, Gunar; Saathoff, Elmar; Rachow, Andrea; Ekandjo, H.; Diergaardt, Azaria; Marais, N.; Lange, Christoph; Nepolo, Emmanuel

doi:10.1128/spectrum.00259-22

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second-line LPA tests for FLQ resistance from mutations affecting codons 90, 91 and 94 of the gyrA gene. Resistance to injectable anti-TB drugs involves mutations in the rrs gene on codons 1401 and 1402, associated with resistance to AMK and KAN, and mutations on codon 1484, associated with resistance to all three drugs (AMK, KAN and CAP) [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic

Farra

Koula

Jolly

et al. 2023

PLOS Glob Public Health

View full text Add to dashboard Cite

The Xpert MTB/RIF and Line Probe Assay (LPA) tests are more and more frequently used in mycobacteria testing laboratories for the rapid diagnosis of multi-drug resistance (MDR-TB). In this study, we demonstrate the effectiveness of these tests in the Central African Republic. Rifampicin resistance cases detected by the Xpert MTB/RIF during the year 2020 are also underwent first- and second-line LPA, and a first-line of drug susceptibility testing (DST) on solid medium and we compared these results. 101 rifampicin resistance cases based on the Xpert MTB/RIF were detected. Mean age was 34 years [16–81]. The 20–40 years age group represented 73.2% and the male-to-female sex ratio was 1.9:1. Patient profiles were dominated by treatment failure cases (40.6%) followed by relapsed cases (30.7%) and new cases (18.8%). These 101 rifampicin resistance were also detected with the first-line LPA and were confirmed by the DST. Similarly, the isoniazid results obtained with the first-line LPA, were confirmed by the DST, giving a concordance of 100% for these antibiotics. Rifampicin resistance were for the most part due to the absence of the WT8 sequence (56%) and the presence of the Mut3 mutation (53.4%). The majority of the isoniazid resistance (94.2%) were due to the Mut1 mutation in the katG gene and 4.2% of the cases involved both the katG gene and the inhA gene promoter with the Mut1 mutation. The second-line LPA test no resistance to second-line antibiotics. This study demonstrated the effectiveness of the Xpert MTB/RIF and the LPA tests for the rapid diagnosis of MDR-TB in the Central African Republic. However, due to their high cost, these tests have not been extensively deployed in the country. Public authorities and their TB-partners can help make these molecular tests more accessible to fight MDR-TB in the country.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic

Farra

Koula

Jolly

et al. 2023

PLOS Glob Public Health

View full text Add to dashboard Cite

show abstract

“…Line probe assays (LPAs), which are based on polymerase chain reaction (PCR), are mainly used to detect drug‐resistant tuberculosis, especially rifampicin (RIF)‐resistant tuberculosis, isoniazid (INH)‐resistant tuberculosis and multidrug‐resistant (MDR) tuberculosis. However, the utility of this method in patients with HIV/TB co‐infection is limited for the following reasons: (a) LPAs requires a sufficient amount of bacillary DNA load, but the acid‐fast bacilli (AFB) load in patients with HIV/TB co‐infection is low [22]; (b) nearly 24%–61% [23] of patients with HIV/TB co‐infection have AFB smear‐negative sputum, and the sensitivity of LPAs for detecting AFB in smear‐negative samples is lower (44.1%) than it is in AFB smear‐positive samples (94.6%) [24]. Therefore, LPAs was recommended only for detecting drug‐resistant TB, and not AFB smear‐negative TB, by the WHO in 2008 (Figure 3) [14].…”

Section: Recent Advances In Molecular Diagnostic Methods For Tubercul...mentioning

confidence: 99%

Bottlenecks and recent advancements in detecting Mycobacterium tuberculosis in patients with HIV

Lin

Sun

Wang

et al. 2023

iLABMED

View full text Add to dashboard Cite

Tuberculosis (TB) remains a leading cause of deaths among patients with acquired immunodeficiency syndrome patients. Early diagnosis of TB is essential for administering timely anti-TB therapy and improving health outcomes, particularly in the people living with HIV. However, conventional techniques used to detect Mycobacterium tuberculosis have significant drawbacks: for example, sputum smear microscopy has low sensitivity, and liquid culture is time-consuming in patients with HIV-TB co-infection due to low sputum production. In addition, while immunological-based methods involving tuberculin skin testing and interferon gamma release assays are commonly used for auxiliary TB diagnosis, they are often inaccurate in immunodeficient patients. Molecular techniques such as line probe assays,

show abstract

Strategic diagnosis- Unraveling Tuberculosis- A comprehensive approach

Wazahat

2024

Indian Journal of Tuberculosis

View full text Add to dashboard Cite

Clinical Evaluation of a Line-Probe Assay for Tuberculosis Detection and Drug-Resistance Prediction in Namibia

Abstract: Mycobacterium tuberculosis ( Mtb ) drug-resistance detection is crucial for successful control of tuberculosis. Line-probe assays (LPA) are frequently used to detect resistance to rifampin, isoniazid, fluoroquinolones (FQs), and second-line injectables (SLIs).

Cited by 4 publications

References 11 publications

Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic

Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic

Bottlenecks and recent advancements in detecting Mycobacterium tuberculosis in patients with HIV

Strategic diagnosis- Unraveling Tuberculosis- A comprehensive approach

Contact Info

Product

Resources

About